Endothelial senescence is induced by phosphorylation and nuclear export of telomeric repeat binding factor 2-interacting protein.
Active Transport, Cell Nucleus
/ physiology
Animals
Apoptosis
Atherosclerosis
/ metabolism
Cellular Senescence
/ drug effects
DNA Damage
Disease Models, Animal
Endothelial Cells
/ metabolism
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Phosphorylation
Plaque, Atherosclerotic
/ metabolism
Shelterin Complex
Signal Transduction
Telomere
Telomere-Binding Proteins
/ genetics
Telomeric Repeat Binding Protein 2
/ genetics
Transcriptome
Atherosclerosis
Cardiology
Signal transduction
Vascular Biology
endothelial cells
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
02 05 2019
02 05 2019
Historique:
received:
14
09
2018
accepted:
19
02
2019
entrez:
3
5
2019
pubmed:
3
5
2019
medline:
9
9
2020
Statut:
epublish
Résumé
The interplay among signaling events for endothelial cell (EC) senescence, apoptosis, and activation and how these pathological conditions promote atherosclerosis in the area exposed to disturbed flow (d-flow) in concert remain unclear. The aim of this study was to determine whether telomeric repeat-binding factor 2-interacting protein (TERF2IP), a member of the shelterin complex at the telomere, can regulate EC senescence, apoptosis, and activation simultaneously, and if so, by what molecular mechanisms. We found that d-flow induced p90RSK and TERF2IP interaction in a p90RSK kinase activity-dependent manner. An in vitro kinase assay revealed that p90RSK directly phosphorylated TERF2IP at the serine 205 (S205) residue, and d-flow increased TERF2IP S205 phosphorylation as well as EC senescence, apoptosis, and activation by activating p90RSK. TERF2IP phosphorylation was crucial for nuclear export of the TERF2IP-TRF2 complex, which led to EC activation by cytosolic TERF2IP-mediated NF-κB activation and also to senescence and apoptosis of ECs by depleting TRF2 from the nucleus. Lastly, using EC-specific TERF2IP-knockout (TERF2IP-KO) mice, we found that the depletion of TERF2IP inhibited d-flow-induced EC senescence, apoptosis, and activation, as well as atherosclerotic plaque formation. These findings demonstrate that TERF2IP is an important molecular switch that simultaneously accelerates EC senescence, apoptosis, and activation by S205 phosphorylation.
Identifiants
pubmed: 31045573
pii: 124867
doi: 10.1172/jci.insight.124867
pmc: PMC6538340
doi:
pii:
Substances chimiques
Shelterin Complex
0
TERF2IP protein, mouse
0
TRF2 protein, mouse
0
Telomere-Binding Proteins
0
Telomeric Repeat Binding Protein 2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118462
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130193
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134740
Pays : United States
Références
Cell. 2000 May 26;101(5):471-83
pubmed: 10850490
Nat Genet. 2000 Dec;26(4):447-50
pubmed: 11101843
Lancet. 2001 Aug 11;358(9280):472-3
pubmed: 11513915
Oncogene. 2002 May 23;21(23):3784-91
pubmed: 12032846
Mol Biol Cell. 2003 Dec;14(12):5060-8
pubmed: 14565979
FASEB J. 2004 Feb;18(2):418-20
pubmed: 14688198
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):546-50
pubmed: 14726417
EMBO Rep. 2005 Mar;6(3):268-74
pubmed: 15731767
Nat Cell Biol. 2005 Jul;7(7):712-8
pubmed: 15968270
Science. 2005 Aug 19;309(5738):1253-6
pubmed: 16037417
Genes Dev. 2005 Sep 15;19(18):2100-10
pubmed: 16166375
Nat Cell Biol. 2006 Aug;8(8):885-90
pubmed: 16845382
Circ Res. 2007 Jan 5;100(1):15-26
pubmed: 17204661
Oncogene. 2008 Mar 13;27(12):1665-76
pubmed: 17891179
Mol Cell Proteomics. 2008 Sep;7(9):1598-608
pubmed: 18463090
J Appl Physiol (1985). 2009 Jan;106(1):326-32
pubmed: 19036896
Exp Gerontol. 2009 Aug;44(8):485-92
pubmed: 19457450
Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1535-43
pubmed: 19684185
J Biol Chem. 2010 Jan 8;285(2):1457-67
pubmed: 19864690
Atherosclerosis. 2010 Mar;209(1):42-50
pubmed: 19889414
Science. 2009 Nov 13;326(5955):948-52
pubmed: 19965504
Science. 2010 Mar 26;327(5973):1657-61
pubmed: 20339076
Nat Cell Biol. 2010 Aug;12(8):768-80
pubmed: 20622869
Nat Cell Biol. 2010 Aug;12(8):758-67
pubmed: 20622870
Exp Gerontol. 2011 Feb-Mar;46(2-3):185-8
pubmed: 20888896
Cell Cycle. 2010 Oct 15;9(20):4061-7
pubmed: 20948311
Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):245-52
pubmed: 21106948
Nat Struct Mol Biol. 2011 Feb;18(2):213-21
pubmed: 21217703
Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):235-6
pubmed: 21248278
Nat Rev Cancer. 2011 Mar;11(3):161-76
pubmed: 21346783
Mol Cell Biochem. 2013 Jan;372(1-2):267-73
pubmed: 23054191
Front Oncol. 2012 Sep 28;2:133
pubmed: 23061047
Circulation. 2013 Jan 29;127(4):486-99
pubmed: 23243209
PLoS One. 2013;8(1):e54514
pubmed: 23342163
Genes Dev. 2013 Jun 15;27(12):1406-20
pubmed: 23756653
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
J Clin Invest. 2014 Jul;124(7):3187-99
pubmed: 24865430
Curr Pharm Des. 2014;20(41):6386-403
pubmed: 24975608
J Clin Invest. 2015 Mar 2;125(3):1299-310
pubmed: 25689261
Cell Cycle. 2015;14(22):3580-92
pubmed: 26505215
Circ Res. 2016 Feb 19;118(4):620-36
pubmed: 26892962
Nat Commun. 2016 Mar 04;7:10881
pubmed: 26941064
Sci Rep. 2017 Feb 27;7:43309
pubmed: 28240303
J Vis Exp. 2017 May 19;(123):
pubmed: 28570508
Microcirculation. 2019 Feb;26(2):e12487
pubmed: 29924435
Cell. 1998 Feb 6;92(3):401-13
pubmed: 9476899